Blam­ing place­bo re­sponse for 'un­in­ter­pretable' PhI­II re­sults, Con­tra­Fect calls for new an­tibi­ot­ic study

Hav­ing spent the past few months comb­ing through the da­ta from a Phase III tri­al that it stopped for fu­til­i­ty, Con­tra­Fect con­clud­ed that it still hasn’t got­ten to the bot­tom of whether its an­tibi­ot­ic works in a type of staph in­fec­tion.

In fact, giv­en the re­sponse rates and safe­ty pro­file it’s seen so far, the biotech says an­oth­er tri­al should be con­duct­ed on the drug, exe­ba­case, in the same pa­tient pop­u­la­tion — ei­ther by Con­tra­Fect it­self or by a part­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER